Brought to you by 
Mimetogen finds new partner for tavilermide in Allergan
01 Jun 2021
Executive Summary
Over a year after Bausch & Lomb let its option expire on Mimetogen Pharmaceuticals Inc.'s tavilermide (MIMD3), Mimetogen found a new partner in Allergan PLC, which has exclusive rights to develop and sell the Phase III topical neurotrophic tyrosine kinase receptor 1 agonist for dry eye syndrome.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com